These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2566199)

  • 21. Neuroleptic effects on electrodermal responsivity to soft tones and loud noise in schizophrenia.
    Green MF; Nuechterlein KH
    Psychiatry Res; 1988 Apr; 24(1):79-86. PubMed ID: 2899332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased urinary peptide excretion in schizophrenic patients after neuroleptic treatment.
    Reichelt KL; Teigland-Gjerstad B
    Psychiatry Res; 1995 Sep; 58(2):171-6. PubMed ID: 8570770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-reported prescribing practices for schizophrenic patients among Israeli psychiatrists.
    Heresco-Levy U; Brom D; Greenberg D
    Isr J Psychiatry Relat Sci; 1993; 30(3):164-74. PubMed ID: 7901179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients.
    Joober R; Rouleau GA; Lal S; Bloom D; Lalonde P; Labelle A; Benkelfat C
    Schizophr Res; 2005 Sep; 77(1):35-41. PubMed ID: 16005383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
    Meltzer HY; Sommers AA; Luchins DJ
    J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time course of antipsychotic effects of neuroleptic drugs.
    Keck PE; Cohen BM; Baldessarini RJ; McElroy SL
    Am J Psychiatry; 1989 Oct; 146(10):1289-92. PubMed ID: 2571305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment refractory schizophrenia].
    Vanelle JM
    Encephale; 1995 Jun; 21 Spec No 3():13-21. PubMed ID: 7628336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The platelet polyphosphoinositide system in schizophrenia: the effects of neuroleptic treatment.
    Essali MA; Das I; de Belleroche J; Hirsch SR
    Biol Psychiatry; 1990 Sep; 28(6):475-87. PubMed ID: 1977477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consent to neuroleptic medication for schizophrenia: clinical, ethical and legal issues.
    Brabbins C; Butler J; Bentall R
    Br J Psychiatry; 1996 May; 168(5):540-4. PubMed ID: 8733791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics.
    Young AS; Faraone SV; Brown WA
    J Clin Psychopharmacol; 1989 Oct; 9(5):361-3. PubMed ID: 2571620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
    Kinon BJ; Kane JM; Chakos M; Munne R
    Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia.
    Tune LE; Creese I; Depaulo JR; Slavney PR; Coyle JT; Snyder SH
    Am J Psychiatry; 1980 Feb; 137(2):187-90. PubMed ID: 6101524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tolerance of neuroleptics, deficit syndrome and cognitive functions].
    Kahn JP
    Encephale; 1996 Jun; 22 Spec No 2():49-54. PubMed ID: 8767043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Profile of the action of neuroleptics in deficit schizophrenia].
    Vanelle JM
    Encephale; 1996 Jun; 22 Spec No 2():33-9. PubMed ID: 8767040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties.
    Möller HJ
    Eur Neuropsychopharmacol; 1993 Mar; 3(1):1-11. PubMed ID: 8097126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neuroleptic malignant syndrome--a case report on diagnosis, differential diagnosis and therapy of a life threatening complication of treatment with neuroleptics].
    Staud L; Pflug B
    Psychiatr Prax; 1992 Jul; 19(4):114-8. PubMed ID: 1354879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Drug abuse experience and neuroleptic prescriptions at the onset of schizophrenia].
    Lisoprawski A
    Sem Hop; 1983 Jun; 59(25):1925-7. PubMed ID: 6136096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.
    Naber D
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():133-8. PubMed ID: 8866775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects.
    Rao ML; Gross G; Strebel B; Bräunig P; Huber G; Klosterkötter J
    Psychiatry Res; 1990 Dec; 34(3):243-57. PubMed ID: 1981623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.